<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03962738</url>
  </required_header>
  <id_info>
    <org_study_id>17012</org_study_id>
    <secondary_id>H8H-JE-LAIH</secondary_id>
    <nct_id>NCT03962738</nct_id>
  </id_info>
  <brief_title>A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine</brief_title>
  <acronym>MONONOFU</acronym>
  <official_title>RandoMized, DOuble-bliNd, PlacebO-coNtrolled Trial Of Lasmiditan in a Single Migraine Attack in Japanese Patients SuFfering From Migraine With or WithoUt Aura - the MONONOFU Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety of lasmiditan in the acute treatment of a
      migraine attack in Japanese adult participants with or without aura.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 31, 2019</start_date>
  <completion_date type="Actual">June 8, 2020</completion_date>
  <primary_completion_date type="Actual">June 8, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants who are Pain Free (High Dose)</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Percentage of Participants who are Pain Free (High Dose)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who are Pain Free in Each Dose Group</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Percentage of Participants who are Pain Free in Each Dose Group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Pain Relief</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Percentage of Participants with Pain Relief</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who are Free of MBS Associated with Migraine</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Percentage of Participants who are Free of the Most Bothersome Symptom as Identified by the Individual from the Associated Symptoms of Nausea, Phonophobia or Photophobia (MBS) Associated with Migraine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with 24-Hour Sustained Pain Freedom</measure>
    <time_frame>24 Hours</time_frame>
    <description>Sustained pain freedom defined as pain free at 2 and 24 hours with no rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with 48-Hour Sustained Pain Freedom</measure>
    <time_frame>48 Hours</time_frame>
    <description>Sustained pain freedom defined as pain free at 2 and 48 hours with no rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants that are Free of Phonophobia</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Percentage of Participants that are Free of Phonophobia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants that are Free of Photophobia</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Percentage of Participants that are Free of Photophobia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants that are Free of Nausea</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Percentage of Participants that are Free of Nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants that are Free of Vomiting</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Percentage of Participants that are Free of Vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Pain Freedom</measure>
    <time_frame>1 Hour Postdose</time_frame>
    <description>Percentage of Participants with Pain Freedom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Pain Relief</measure>
    <time_frame>1 Hour Postdose</time_frame>
    <description>Percentage of Participants with Pain Relief</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Freedom from MBS</measure>
    <time_frame>1 Hour Postdose</time_frame>
    <description>Percentage of Participants with Freedom from MBS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Disability</measure>
    <time_frame>1 Hour Postdose</time_frame>
    <description>Percentage of Participants with No Disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Disability</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Percentage of Participants with No Disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the EuroQol 5 Dimension 5-level scale (EQ-5D-5L)</measure>
    <time_frame>24 Hours Postdose</time_frame>
    <description>Change from Baseline on the EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Very Much or Much Better as Measured by the Patient Global Impression of Change (PGI-C)</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Percentage of Participants Very Much or Much Better as Measured by the PGI-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL) Total Score as Measured by the 24-Hour Migraine Quality of Life Questionnaire (MQoLQ)</measure>
    <time_frame>24 Hours Postdose</time_frame>
    <description>HRQoL Total Score as Measured by the 24-Hour MQoLQ</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">846</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Lasmiditan Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lasmiditan given orally and placebo given orally to maintain the blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lasmiditan given orally and placebo given orally to maintain the blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasmiditan High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lasmiditan given orally and placebo given orally to maintain the blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Lasmiditan High Dose</arm_group_label>
    <arm_group_label>Lasmiditan Low Dose</arm_group_label>
    <arm_group_label>Lasmiditan Mid Dose</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Lasmiditan High Dose</arm_group_label>
    <arm_group_label>Lasmiditan Low Dose</arm_group_label>
    <arm_group_label>Lasmiditan Mid Dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with migraine with or without aura fulfilling the International
             Classification of Headache Disorders (ICHD)-2.

          -  History of disabling migraine for at least 1 year.

          -  Migraine Disability Assessment Test (MIDAS) score â‰¥11.

          -  Migraine onset before the age of 50 years.

          -  History of 3-8 migraine attacks per month and &lt;15 headache days per month during the
             past 3 months.

        Exclusion Criteria:

          -  Known hypersensitivity to lasmiditan, or to any excipient of lasmiditan oral tablets.

          -  History or evidence of hemorrhagic stroke, epilepsy, or any other condition placing
             the patient at increased risk of seizures.

          -  History of recurrent dizziness and/or vertigo including benign paroxysmal positional
             vertigo, Meniere's disease, vestibular migraine, and other vestibular disorders.

          -  History of diabetes mellitus with complications (diabetic retinopathy, nephropathy, or
             neuropathy).

          -  History of orthostatic hypotension with syncope.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Takanoko Hospital</name>
      <address>
        <city>Matsuyama-shi</city>
        <state>Ehime</state>
        <zip>790-0925</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikeda Neurosurgical Clinic</name>
      <address>
        <city>Kasuga-shi</city>
        <state>Fukuoka</state>
        <zip>816 0824</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinnouchi Neurosurgery Clinic</name>
      <address>
        <city>Kasuga-shi</city>
        <state>Fukuoka</state>
        <zip>816-0802</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUBARU Health Insurance Society Ota Memorial Hospital</name>
      <address>
        <city>Ota-shi</city>
        <state>Gunma</state>
        <zip>373-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakamura Memorial Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060 8570</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kohnan Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>658-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamaguchi Clinic</name>
      <address>
        <city>Nishinomiya-shi</city>
        <state>Hyogo</state>
        <zip>663-8204</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nishinomiya Municipal Central Hospital</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujitsu Clinic</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>211-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sendai Headache and Neurology Clinic</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>982-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama City General Medical Center Okayama City Hospital</name>
      <address>
        <city>Okayama-shi</city>
        <state>Okayama</state>
        <zip>700-8557</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chibune General Hospital</name>
      <address>
        <city>Osaka-City</city>
        <state>Osaka</state>
        <zip>555-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takase internal medicine clinic</name>
      <address>
        <city>Toyonaka-shi</city>
        <state>Osaka</state>
        <zip>560-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osoegawa Neurology Clinic</name>
      <address>
        <city>Saga-shi</city>
        <state>Saga</state>
        <zip>840-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University Hospital</name>
      <address>
        <city>Iruma-Gun</city>
        <state>Saitama</state>
        <zip>350-0495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Neuropsychiatric Institute</name>
      <address>
        <city>Saitama City</city>
        <state>Saitama</state>
        <zip>338-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saino Clinic</name>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <zip>359-1141</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokkyo Medical University Hospital</name>
      <address>
        <city>Shimotsuga-Gun</city>
        <state>Tochigi</state>
        <zip>321 0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niwa Family Clinic</name>
      <address>
        <city>Chofu-shi</city>
        <state>Tokyo</state>
        <zip>182-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanno Clinic Shinagawa</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USUDA CLINIC for internal medicine</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>156-0043</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Headache Clinic</name>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <zip>151-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuuchi Pain Clinic</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakura Clinic Internal Medicine Neurology</name>
      <address>
        <city>Toyama-Shi</city>
        <state>Toyama</state>
        <zip>9300803</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagaseki Headache Clinic</name>
      <address>
        <city>Kai-Shi</city>
        <state>Yamanashi</state>
        <zip>400-0124</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doi Clinic Internal Medicine Neurology</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanaka neurosurgical clinic</name>
      <address>
        <city>Kagoshima</city>
        <zip>892-0844</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umenotsuji Clinic</name>
      <address>
        <city>Kochi</city>
        <zip>780-8011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto City Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>862-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tatsuoka Neurology Clinic</name>
      <address>
        <city>Kyoto</city>
        <zip>600-8811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ishikawa Clinic</name>
      <address>
        <city>Kyoto</city>
        <zip>606-0851</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Saiseikai Nakatsu Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>530-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tominaga Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>5560017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Shizuoka Hospital</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

